Oligonucleotide Therapeutics First Annual Meeting of the Ol (Perfect) Product Description
Oligonucleotide Therapeutics First Annual Meeting of the Ol his volume concentrates on the most relevant oligonucleotide research and drug development areas and emphasizes the basic mechanisms and biology of oligonucleotide reagents.hapters are devoted to RNAi, oligonucleotide delivery, and immunomodulation. Because of the advanced stages of oligonucleotide-based drug development, preclinical and clinical data are also presented by leaders in the field.OTE Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit www.blackwellpublishing.comnyas.CADEMY MEMBERS Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full-text access to the Annals online and discounts on print volumes. Please visit www.nyas.orgmembershipmain.asp for more information about becoming a member. I. Delivery1. Targeted Delivery of Antisense Oligonucleotide and Small Interference RNA into Lung Cancer Cells Shyh-Dar Li2. Atelocollagen-Mediated Systemic DDS for Nucleic Acid Medicines Koji Hanai3. Intracellular Delivery of Oligonucleotide Conjugates and Dendrimer Complexes R.L. Juliano4. Mechanism of PNA Transport to the Nuclear Compartment Lenka Stankova, Amy J. Ziemba, Zhanna V. Zhilina, and Scot W. EbbinghausII. Immunomodulation5. The Concept of Immunostimulatory Nucleic Acids CpG, the Plasmacytoid Dendritic Cell and Beyond Gunther Hartmann6. Molecular Interaction of Toll-Like Receptor 9 and Nucleic Acid Eicke Latz7. Effects of CpG ODN on Plasmacytoid Dendritic Cell-Induced Generation of Regulatory T Cells and Immune Tolerance Wei Chen8. Induction of an Apoptotic Pathway in CLL Cells Stimulated by CpG ODN George J. WeinerIII. Identifying and Validating Targets and Systems9. RNA Silencing in the Struggle Against Disease Volker Patzel, Isabell Dietrich Stefan H. E. Kaufmann10. shRNA as antiHIV Therapy John J. Rossi11. Cellular Dynamics of Antisense Oligonucleotides and Short Interfering RNAs Li Kim Lee, Brandee M. Dunham, Zhuting Li, and Charles M. Roth12. Inhibition of Hepatitis C IRES-mediated Gene Expression by Small Hairpin RNAs in Human Hepatocytes and Mice Roger L. Kaspar, Qian Wang, Attila A. Seyhan, Heini Ilves, Alexander V. Vlassov, Christopher H. Contag, and Brian H. Johnston13. SiRNA-mediated Selective Inhibition of Mutant Keratin mRNAs Responsible for the Skin Disorder Pachyonychia Congenital Robyn P. Hickerson, Frances J. D. Smith, W. H. Irwin McLean, Markus Landthaler, Rudolf Leube and Roger L. Kaspar14. Importance of Pharmacodynamic Studies- Discovering Real Mechanisms of Action Cy A. Stein15. Multi-targeted Approach Using Antisense Oligonucleotides for the Treatment of Asthma Z. Allakhverdia, M. Allama, A. Guimondb, N. Ferrari, K. Zemzoumib,R. S guinb, L. Paquetb and P. M. Renzi16. Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense Olig
|
Oligonucleotide Therapeutics First Annual Meeting of the Ol (Perfect)
